Influenza is one of those Step 1 “looks simple until it isn’t” viruses: same family, same symptoms… but wildly different implications depending on whether you’re dealing with antigenic drift (seasonal epidemics) or antigenic shift (pandemics). If you can clearly explain why drift happens every year and why shift is rare but dangerous, you’ve basically locked in a whole cluster of virology, immunology, and pharm questions.
Big Picture: What Is Influenza?
Influenza is an Orthomyxovirus that causes acute respiratory illness and systemic symptoms (classic “flu” picture). It’s a top-tier USMLE organism because it links:
- Viral structure → replication strategy → mutation
- Surface proteins (HA/NA) → immunity → vaccines
- Epidemiology (drift vs shift) → public health
- Treatment timing → clinical outcomes
First Aid Cross-References (by concept)
(Edition/page numbers vary; use these as “where to look” anchors.)
- Orthomyxovirus fundamentals (segmented RNA, nucleus replication, drift/shift)
- HA/NA and antigenic variation
- Antiviral drugs: oseltamivir/zanamivir, baloxavir
- Vaccine principles: inactivated vs live-attenuated; annual updates
Classification & Structure (High Yield)
Virus Family: Orthomyxoviridae
Key properties you should be able to rattle off:
| Feature | Influenza (Orthomyxo) | Why it matters |
|---|---|---|
| Genome | (-) ssRNA | Must carry RNA-dependent RNA polymerase |
| Segmented? | Yes (segmented) | Enables reassortment → antigenic shift |
| Envelope | Enveloped | More fragile; spread via respiratory droplets |
| Replication site | Nucleus (unusual for RNA viruses) | Enables “cap snatching” + classic board-style questions |
| Major surface proteins | Hemagglutinin (HA), Neuraminidase (NA) | Targets of immunity + drift/shift + antivirals |
Pathophysiology: How Influenza Causes Disease
Step 1-level mechanism
- HA binds sialic acid on respiratory epithelial cells → viral entry via endocytosis.
- Viral replication occurs with a twist: transcription/replication in the nucleus.
- Virus assembles and buds from the cell membrane.
- NA cleaves sialic acid → helps release budding virions and prevents them from clumping on the cell surface.
What causes symptoms?
- Direct epithelial damage + innate immune cytokines → fever, myalgias, malaise.
- Predisposes to secondary bacterial pneumonia because damaged mucosa can’t clear bacteria effectively.
The Two Concepts Everyone Mixes Up: Antigenic Drift vs Antigenic Shift
Quick definitions (memorize these)
- Antigenic drift = gradual change due to point mutations in HA and/or NA.
- Antigenic shift = abrupt change due to reassortment of genome segments → new HA and/or NA subtype.
Side-by-side comparison (the exam’s favorite table)
| Feature | Antigenic drift | Antigenic shift |
|---|---|---|
| Mechanism | Point mutations (RNA polymerase lacks proofreading) | Reassortment of segmented genomes |
| Speed | Gradual | Sudden |
| Clinical impact | Seasonal epidemics | Pandemics |
| Who gets it? | Influenza A and B | Influenza A only |
| Immunity | Partial escape → reinfections | Major escape → population highly susceptible |
| Step clue | “New strain this season” | “New subtype; global outbreak; reassorted from animal reservoir” |
Why shift is Influenza A only (HY reasoning)
- Influenza A has a large animal reservoir (birds, pigs, etc.), enabling co-infection with different strains in one host → segment mixing.
- Influenza B is mostly human-restricted → drift happens, but shift is not the classic pattern.
The “mixing vessel” concept (classic board phrasing)
- Pigs can be infected by both avian and human influenza strains → reassortment → novel strain with a new HA/NA combination.
Clinical Presentation (Step 1 → Step 2 bridge)
Typical influenza (uncomplicated)
Abrupt onset (hours, not days) of:
- Fever
- Myalgias
- Headache
- Malaise
- Dry cough ± sore throat, rhinorrhea
High-yield distinguishing feature:
Influenza tends to cause prominent systemic symptoms (myalgias, fever) compared with many other viral URIs.
Red flags / complications (testable)
- Primary influenza pneumonia (viral pneumonia)
- Progressive dyspnea, hypoxemia
- Diffuse interstitial infiltrates
- Can be severe in pregnancy, elderly, comorbid patients
- Secondary bacterial pneumonia (very classic)
- Often initial improvement then recurrence of fever/cough
- Common organisms:
- Staphylococcus aureus (including MRSA)
- Streptococcus pneumoniae
- Haemophilus influenzae
- Reye syndrome (boards classic)
- Child with viral illness + aspirin → vomiting, encephalopathy, hepatic dysfunction
- Often associated with influenza (and varicella)
- Myositis/rhabdomyolysis, otitis media (kids)
- Exacerbation of asthma/COPD
- Rare neuro: encephalitis, transverse myelitis (less Step 1, but possible)
High-risk groups (who you treat early)
- Age <5 (esp <2) and ≥65
- Pregnant and postpartum
- Chronic cardiopulmonary disease, diabetes, CKD, immunocompromised
- Residents of nursing homes/long-term care
Diagnosis: What They Expect You to Know
Many questions are clinical-diagnosis based
- In an otherwise healthy person during flu season with classic symptoms → clinical diagnosis is common.
Tests (know the buzzwords)
- Rapid influenza diagnostic tests (RIDTs)
- Fast, but sensitivity can be limited → false negatives
- RT-PCR
- More sensitive/specific; common in hospitals
Don’t confuse with other respiratory viruses
- Parainfluenza → croup (barking cough, inspiratory stridor)
- RSV → bronchiolitis in infants
- Adenovirus → pharyngoconjunctival fever
- Rhinovirus → common cold, mild systemic symptoms
Treatment (Very Testable): When and What to Use
Core principle
Antivirals work best if started within 48 hours of symptom onset (Step favorite).
Neuraminidase inhibitors (block viral release)
- Oseltamivir (oral)
- Zanamivir (inhaled)
Mechanism: inhibit neuraminidase (NA) → prevents release of virions from infected cells.
High-yield adverse effect:
- Zanamivir can cause bronchospasm → avoid/use caution in asthma/COPD (common vignette trap).
Baloxavir (newer board-relevant concept)
- Baloxavir marboxil inhibits influenza cap-dependent endonuclease → blocks “cap snatching,” impairing viral mRNA synthesis.
Supportive care
- Fluids, antipyretics (avoid aspirin in kids), rest.
Treatment vs prophylaxis (test logic)
- Treat: confirmed/suspected flu in high-risk patients, severe disease, hospitalized patients, or early presentation.
- Post-exposure prophylaxis may be used in high-risk exposures (institutional outbreaks, vulnerable contacts), often with oseltamivir.
Prevention: Vaccines & What Drift Means for the Shot
Why is the flu vaccine annual?
Because antigenic drift changes HA/NA epitopes gradually, so last year’s antibodies may be less protective. Surveillance predicts dominant strains, then the vaccine is updated.
Vaccine types (high yield)
- Inactivated (killed) vaccine: injectable; generally safe in pregnancy and immunocompromised.
- Live-attenuated intranasal vaccine: not for immunocompromised; avoid in certain high-risk groups.
What the vaccine mainly targets
Neutralizing antibodies against hemagglutinin (HA) are especially important (prevent attachment/entry).
High-Yield USMLE Associations & “If You See This, Think Influenza”
1) “Segmented, negative-sense RNA that replicates in the nucleus”
- Think Orthomyxovirus (influenza).
- Segmentation → reassortment → shift.
2) “New pandemic strain after reassortment in pigs/birds”
- Think antigenic shift → Influenza A → pandemic potential.
3) “Seasonal epidemics with point mutations”
- Think antigenic drift → Influenza A and B.
4) “Child with viral illness given aspirin → encephalopathy + fatty liver”
- Think Reye syndrome (influenza or varicella association).
5) “After flu, patient worsens with productive cough and high fever”
- Think secondary bacterial pneumonia (S. aureus, S. pneumo, H. influenzae).
6) “Asthmatic given inhaled flu med then wheezes”
- Think zanamivir → bronchospasm.
Rapid Review: Your 30-Second Checklist
- Orthomyxovirus: enveloped, (-) ssRNA, segmented, nucleus replication
- Surface proteins: HA (attachment), NA (release)
- Drift: point mutations → seasonal epidemics (A and B)
- Shift: reassortment → pandemics (A only)
- Treat early (≤48h): oseltamivir/zanamivir (NA inhibitors), baloxavir (cap endonuclease)
- Complications: primary viral pneumonia, secondary bacterial pneumonia, Reye syndrome